Last reviewed · How we verify
Semaglutide Pen Injector [Ozempic]
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight.
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | Semaglutide Pen Injector [Ozempic] |
|---|---|
| Also known as | Ozempic, Wegovy, Ozempic Injectable Product, Semaglutide 1mg |
| Sponsor | University of Nottingham |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, slows gastric emptying to reduce postprandial glucose spikes, and acts on the central nervous system to suppress appetite and increase satiety. These combined effects result in improved glycemic control and significant weight loss.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia (when combined with insulin or sulfonylureas)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Pen Injector [Ozempic] CI brief — competitive landscape report
- Semaglutide Pen Injector [Ozempic] updates RSS · CI watch RSS
- University of Nottingham portfolio CI